Book contents
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part 1.1 Analytical techniques: analysis of DNA
- Part 1.2 Analytical techniques: analysis of RNA
- Part 2.1 Molecular pathways underlying carcinogenesis: signal transduction
- Part 2.2 Molecular pathways underlying carcinogenesis: apoptosis
- Part 2.3 Molecular pathways underlying carcinogenesis: nuclear receptors
- Part 2.4 Molecular pathways underlying carcinogenesis: DNA repair
- Part 2.5 Molecular pathways underlying carcinogenesis: cell cycle
- Part 2.6 Molecular pathways underlying carcinogenesis: other pathways
- Part 3.1 Molecular pathology: carcinomas
- Part 3.2 Molecular pathology: cancers of the nervous system
- Part 3.3 Molecular pathology: cancers of the skin
- Part 3.4 Molecular pathology: endocrine cancers
- Part 3.5 Molecular pathology: adult sarcomas
- Part 3.6 Molecular pathology: lymphoma and leukemia
- Part 3.7 Molecular pathology: pediatric solid tumors
- Part 4 Pharmacologic targeting of oncogenic pathways
- 78 Oncology drug discovery for biologics: antibody development strategies and considerations
- 79 Targeting the EGFR family of receptor tyrosine kinases
- 80 Therapeutic approaches with antibodies to cell-surface receptors
- 81 Signal transduction in tumor angiogenesis
- 82 Tyrosine-kinase inhibitors in oncology
- 83 Anti-estrogens and selective estrogen-receptor modulators
- 84 Therapeutic applications of anti-sense mechanisms for the treatment of cancer
- 85 Induction of apoptosis
- 86 DNA-methylation inhibitors
- 87 Histone deacetylase inhibitors
- 88 Drug resistance: as complex and diverse as the disease itself
- 89 Molecular profiling and therapeutic decision-making: the promise of personalized medicine
- 90 DNA repair inhibition in anti-cancer therapeutics
- Index
- References
79 - Targeting the EGFR family of receptor tyrosine kinases
from Part 4 - Pharmacologic targeting of oncogenic pathways
Published online by Cambridge University Press: 05 February 2015
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part 1.1 Analytical techniques: analysis of DNA
- Part 1.2 Analytical techniques: analysis of RNA
- Part 2.1 Molecular pathways underlying carcinogenesis: signal transduction
- Part 2.2 Molecular pathways underlying carcinogenesis: apoptosis
- Part 2.3 Molecular pathways underlying carcinogenesis: nuclear receptors
- Part 2.4 Molecular pathways underlying carcinogenesis: DNA repair
- Part 2.5 Molecular pathways underlying carcinogenesis: cell cycle
- Part 2.6 Molecular pathways underlying carcinogenesis: other pathways
- Part 3.1 Molecular pathology: carcinomas
- Part 3.2 Molecular pathology: cancers of the nervous system
- Part 3.3 Molecular pathology: cancers of the skin
- Part 3.4 Molecular pathology: endocrine cancers
- Part 3.5 Molecular pathology: adult sarcomas
- Part 3.6 Molecular pathology: lymphoma and leukemia
- Part 3.7 Molecular pathology: pediatric solid tumors
- Part 4 Pharmacologic targeting of oncogenic pathways
- 78 Oncology drug discovery for biologics: antibody development strategies and considerations
- 79 Targeting the EGFR family of receptor tyrosine kinases
- 80 Therapeutic approaches with antibodies to cell-surface receptors
- 81 Signal transduction in tumor angiogenesis
- 82 Tyrosine-kinase inhibitors in oncology
- 83 Anti-estrogens and selective estrogen-receptor modulators
- 84 Therapeutic applications of anti-sense mechanisms for the treatment of cancer
- 85 Induction of apoptosis
- 86 DNA-methylation inhibitors
- 87 Histone deacetylase inhibitors
- 88 Drug resistance: as complex and diverse as the disease itself
- 89 Molecular profiling and therapeutic decision-making: the promise of personalized medicine
- 90 DNA repair inhibition in anti-cancer therapeutics
- Index
- References
Summary
General structure
Epidermal growth-factor receptor (EGFR) proteins or erythroblastic leukemia viral oncogene homolog (ERBB) proteins are a group of transmembrane receptors with intrinsic tyrosine kinase activity. The EGFR family is one of the most important groups of transmembrane cell surface receptors that integrate extra-cellular signals (e.g. growth factors, cytokines, and hormones) to drive multiple critical cellular processes, including cell proliferation, differentiation, and survival, via localized paracrine signals (1). EGFR family proteins are classified as subclass I receptor tyrosine kinases (RTKs; Figure 79.1), containing four structurally related RTKs (2): EGFR (also known as ERBB-1/HER1), ERBB-2 (HER2 in humans and Neu in rodents), ERBB-3 (HER3), and ERBB-4 (HER4). Each EGFR family receptor has an extra-cellular ligand-binding domain, a single α-helix transmembrane domain, an intra-cellular tyrosine kinase domain (with the exception of ERBB-3/HER3) and a cytoplasmic tail with tyrosine autophosphorylation sites (3; Figure 79.2). Although all four of these members share a similar domain structure, each has unique properties. EGFR (ERBB1) and ERBB4 have several known extra-cellular ligands and tyrosine-kinase activity on their cytoplasmic tail. ERBB2 has a similar active tyrosine-kinase domain. However, no direct ligand for ERBB2 has been identified. The other member, ERBB3 is characterized by a lack of tyrosine-kinase activity, although it binds to its extra-cellular ligands (4,5).
- Type
- Chapter
- Information
- Molecular OncologyCauses of Cancer and Targets for Treatment, pp. 843 - 853Publisher: Cambridge University PressPrint publication year: 2013